HBIO Announces Details of Approved Spin-Off of Harvard Apparatus Regenerative Technology, Inc.

HBIO Announces Details of Approved Spin-Off of Harvard Apparatus Regenerative
Technology, Inc.

Record Date for Share Distribution Set for October 21, 2013

HOLLISTON, Mass., Oct. 16, 2013 (GLOBE NEWSWIRE) -- The Board of Directors of
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and
marketer of a broad range of tools to advance life science research and
regenerative medicine, has approved the spin-off of its wholly owned
regenerative medicine device subsidiary, Harvard Apparatus Regenerative
Technology, Inc., or HART.

To implement the spin-off distribution, Harvard Bioscience will distribute all
of its shares of HART common stock on a pro rata basis to those stockholders
that hold Harvard Bioscience common stock at the close of business on October
21, 2013, the Record Date for the distribution. Each such shareholder of
Harvard Bioscience common stock will receive one share of HART common stock
for every four shares of Harvard Bioscience common stock that such shareholder
holds at the close of business on the Record Date. The distribution will be
effective as of November 1, 2013. As a result of the spin-off, Harvard
Bioscience will no longer own any shares of HART common stock and HART will be
an independent public company.

The dividend of HART common stock will be issued in book-entry form only,
which means that no physical HART stock certificates will be issued. Harvard
Bioscience will not distribute any fractional shares of HART's common stock.
Instead the transfer agent, Registrar & Transfer Company, will aggregate
fractional shares into whole shares, sell the whole shares in the open market
and distribute the aggregate net cash proceeds of the sales pro rata (based on
the fractional share such holder would otherwise be entitled to receive) to
each holder who otherwise would have been entitled to receive a fractional
share in the distribution. Harvard Bioscience stockholders will not be
required to make any payment; surrender or exchange their shares of Harvard
Bioscience common stock; or, take any other action to receive shares of HART
common stock.

For additional information, stockholders should contact Registrar & Transfer
Company by e-mail at info@rtco.com or by phone at 800-456-0596. Prior to the
Distribution Date, a comprehensive information statement will be mailed to
Harvard Bioscience stockholders of record on the Record Date.

Harvard Bioscience expects a "when issued" public market for HART common stock
to begin on or about October 21, 2013 on the NASDAQ Capital Market under the
ticker symbol "HART." Following the spin-off, "regular way" trading of HART
common stock is expected to start on November 4, 2013 under that "HART" ticker
symbol. Harvard Bioscience's common stock will continue to trade on the NASDAQ
Global Market under the symbol "HBIO." If Harvard Bioscience stockholders sell
shares of their Harvard Bioscience common stock in the "regular way" market
after the Record Date but prior to the Distribution Date, they may also be
selling the right to receive shares of HART common stock in connection with
those shares. Investors are advised to consult with their financial advisors
about selling their shares of Harvard Bioscience common stock on or before the
Distribution Date.


Some of the statements in this press release are "forward-looking" and are
made pursuant to the safe harbor provision of the Private Securities
Litigation Reform Act of 1995. These "forward-looking" statements include
statements relating to, among other things, the intention to consummate the
spin-off of Harvard Apparatus Regenerative Technology, the related Form 10
filing with the SEC and NASDAQ Capital Market listing and the availability of
a market for the HART securities. These statements involve risks and
uncertainties, including among other things, market and other conditions that
may cause results to differ materially from the statements set forth in this
press release. There can be no assurance that such statements and information
will prove to be accurate as actual results and future events could differ
materially from those anticipated in such statements and information. The
forward-looking statements in this press release speak only as of the date of
this press release. Harvard Bioscience expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to such statements to
reflect any change in its expectations with regard thereto or any changes in
the events, conditions or circumstances on which any such statement is based.

For investor inquiries, please call (508) 893-8066. Press releases may be
found on our web site, http://www.harvardbioscience.com.

The Harvard Bioscience, Inc. logo is available at

CONTACT: Jeffrey Duchemin
         Chief Executive Officer
         Tel: 508 893 8999
         Fax: 508 892 6135
         David Green
         Tom McNaughton

Harvard Bioscience, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.